ExonHit and Institut Gustave Roussy sign breast cancer diagnostic deal
This article was originally published in Clinica
Executive Summary
ExonHit Therapeutics has signed an exclusive worldwide licence agreement to develop and commercialise Institut Gustave Roussy's novel breast cancer diagnostic.